Efficacy of regimens combining direct acting antiviral agents for hepatitis C virus recombinant form RF1_2k/1b

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|48|1|3-4

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.48, Iss.1, 2018-01, pp. : 3-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 36-44

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will IL28B polymorphism remain relevant in the era of direct‐acting antiviral agents for hepatitis C virus?

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 373-381

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

By  

Oncology, Vol. 93, Iss. 2, 2017-04 ,pp. : 92-98

Karger

Access to resources Recommend Favorite

Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 7-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acquired hemophilia A resolution in a hepatitis C virus/human immunodeficiency virus–coinfected patient with cure of hepatitis C by direct‐acting antiviral agents

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 794-796

John Wiley & Sons Inc

Access to resources Recommend Favorite